Table 2.
Unadjusted Differences From Baseline to Follow-Up for Cardiovascular Disease Clinical Indicators, Project HEART, El Paso, Texas, 2005-2008
| Clinical Indicator | Control Group (n = 136) | P Valuea | Experimental Group (n = 192) | P Valuea | ||
|---|---|---|---|---|---|---|
|
|
|
|||||
| Baseline | 4-Month Follow-Up | Baseline | 4-Month Follow-Up | |||
| Mean (SD) | ||||||
| Body mass index, kg/m2 | 31.1 (6.4) | 31.2 (6.5) | .28 | 31.7 (6.8) | 31.6 (6.7) | .34 |
| Weight, lb | 183.1 (42.5) | 183.0 (43.0) | .84 | 181.8 (39.1) | 180.5 (40.0) | .01 |
| Waist circumference, in | 40.2 (6.0) | 41.0 (5.7) | .01 | 40.6 (5.8) | 40.7 (5.9) | .49 |
| Framingham risk scoreb | 14.3 (11.9) | 9.3 (7.0) | <.001 | 15.5 (13.2) | 10.8 (7.9) | <.001 |
| Metabolic syndrome, mean no. of risk factors | 2.4 (1.3) | 2.6 (1.3) | .01 | 2.4 (1.2) | 2.7 (1.2) | <.001 |
| LDL cholesterol, mg/dL | 120.2 (31.9) | 119.8 (33.6) | .86 | 127.6 (36.2) | 121.3 (38.0) | .01 |
| HDL cholesterol, mg/dL | 42.6 (10.7) | 41.5 (11.2) | .11 | 40.6 (11.2) | 40.6 (10.0) | .97 |
| Total cholesterol, mg/dL | 190.5 (38.5) | 190.5 (42.4) | .99 | 197.5 (48.5) | 192.3 (54.5) | .03 |
| Non-HDL cholesterol, mg/dL | 147.9 (37.7) | 148.9 (42.9) | .69 | 155.1 (41.5) | 149.3 (43.1) | .01 |
| Triglyceride level, mg/dL | 139.1 (82.8) | 139.2 (91.7) | .98 | 134.7 (71.5) | 140.9 (77.5) | .21 |
| Fasting blood glucose, mg/dL | 95.3 (31.7) | 99.8 (40.7) | .09 | 101.5 (40.3) | 105.2 (44.3) | .10 |
| HbA1c, % | 6.3 (1.3) | 6.5 (1.3) | .01 | 6.6 (1.5) | 6.6 (1.5) | .83 |
| Systolic blood pressure, mm Hg | 141.4 (20.5) | 132.6 (17.5) | <.001 | 137.2 (21.8)c | 131.9 (19.2) | <.001 |
| Diastolic blood pressure, mm Hg | 89.4 (16.3) | 78.3 (10.8) | <.001 | 80.0 (10.9)c | 77.6 (9.4) | .01 |
| Prevalence, % | ||||||
| Smoking | 30 | 21 | .09 | 27 | 19 | .07 |
| Diabetesd | 30 | 34 | .50 | 35 | 40 | .32 |
| Systolic hypertensiond | 45 | 29 | .01 | 37 | 29 | .11 |
| Systolic prehypertensiond | 40 | 45 | .40 | 36 | 41 | .32 |
| Diastolic hypertensiond | 41 | 16 | <.001 | 21 | 10 | .01 |
| Diastolic prehypertensiond | 28 | 24 | .46 | 28 | 25 | .55 |
| Taking hypertension medicatione | 41 | 40 | .78 | 42 | 45 | .59 |
| Taking lipid-lowering medicatione | 27 | 29 | .63 | 29 | 35 | .28 |
| Taking diabetes medicatione | 26 | 22 | .52 | 29 | 30 | .79 |
Abbreviations: HEART, Health Education Awareness Research Team; SD, standard deviation; LDL, low-density lipoprotein; HDL, high-density lipoprotein; HbA1c, hemoglobin A1c.
P values were calculated by using paired-samples t tests.
Framingham score based on age, LDL cholesterol, HDL cholesterol, smoking status, diabetes diagnosis (self-report, HbA1c >7%, or fasting glucose >126 mg/dL).
Significantly different from control at baseline, P < .05.
Diabetes defined as HbA1c >7%, fasting blood glucose >126 mg/dL, or self-report; systolic hypertension defined as >140 mm Hg and prehypertension defined as >120 mm Hg; diastolic hypertension defined as >90 mm Hg and prehypertension defined as >80 mm Hg.
All variables regarding medication intake are self-reported.